Postmortem examinations of patients, where the procedure commences shortly after death (rapid autopsies), are becoming an important scientific engine for understanding mechanisms of disease progression and drug resistance, especially in this era of personalized medicine and immunotherapy. Recently, the Department of Pathology and the Sidney Kimmel Comprehensive Cancer Center (SKCCC) recruited a new Director of Autopsy with a strong interest in rapid autopsy. The new Director started the Johns Hopkins Legacy Gift Rapid Autopsy Program, and it recently became an SKCCC Rapid Autopsy Program (RAP) Core. RAP Core members will: 1) Perform rapid autopsies on cancer patients for studies related to therapeutic resistance mechanisms, immune evasion and correlation of molecular markers with clinical trial outcomes. 2) Provide expert consultation and quality control/assurance in interpretation of autopsy histopathology samples, including fresh frozen tissues. 3) Aid SKCCC and other investigators by providing administrative, technical and logistical support for performing rapid autopsies on patients with all tumor types. 4) Expand and maintain a biorepository of fresh frozen tissues, FFPE tissues and fluid specimens from rapid autopsy cases, with full pathology and clinical annotations that can be accessed by qualified SKCCC investigators. 5) Carry out molecular pathology-based biospecimen science studies to aid in the development and extension of best practices for tissue procurement, derivative specimen handling and sample storage. The Core utilizes the state-of-the-art Johns Hopkins Hospital postmortem facility. SKCCC-Managed Core Current Grant Year Reporting Period: Jan. 1, 2015, to Dec. 31, 2015

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Adler, B L; Pezhouh, M K; Kim, A et al. (2018) Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis. J Intern Med 283:568-577
Anchoori, Ravi K; Jiang, Rosie; Peng, Shiwen et al. (2018) Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer. ACS Omega 3:11917-11929
Shanbhag, Satish; Ambinder, Richard F (2018) Hodgkin lymphoma: A review and update on recent progress. CA Cancer J Clin 68:116-132
Palsgrove, Doreen N; Brosnan-Cashman, Jacqueline A; Giannini, Caterina et al. (2018) Subependymal giant cell astrocytoma-like astrocytoma: a neoplasm with a distinct phenotype and frequent neurofibromatosis type-1-association. Mod Pathol 31:1787-1800
Kelley, Dylan Z; Flam, Emily L; Guo, Theresa et al. (2018) Functional characterization of alternatively spliced GSN in head and neck squamous cell carcinoma. Transl Res 202:109-119
Knapp, Emily A; Dean, Lorraine T (2018) Consumer credit scores as a novel tool for identifying health in urban U.S. neighborhoods. Ann Epidemiol 28:724-729
Forde, Patrick M; Chaft, Jamie E; Smith, Kellie N et al. (2018) Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med 378:1976-1986
Cottrell, Tricia R; Duong, Anh T; Gocke, Christopher D et al. (2018) PD-L1 expression in inflammatory myofibroblastic tumors. Mod Pathol 31:1155-1163
Fackler, Mary Jo; Sukumar, Saraswati (2018) Quantitation of DNA Methylation by Quantitative Multiplex Methylation-Specific PCR (QM-MSP) Assay. Methods Mol Biol 1708:473-496
Converse, Paul J; Almeida, Deepak V; Tasneen, Rokeya et al. (2018) Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer. PLoS Negl Trop Dis 12:e0006728

Showing the most recent 10 out of 2393 publications